nelfinavir has been researched along with Disease Exacerbation in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Azoulay, S; Dani, C; Darini, CY; Drici, MD; Hofman, P; Ladoux, A; Martin, P; Obba, S | 1 |
| De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Panes, R; Ryazanov, AG; Zaffalon, L | 1 |
| Belohradsky, BH; Eberle, J; Funk, M; Gürtler, L; Hoffmann, F; Linde, R; Notheis, G; Petropoulou, T; Wintergerst, U | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Scherpbier, HJ; van Leth, F | 1 |
| Asensi, V; Cartón, JA; Collazos, J | 1 |
| Asboe, D; Babiker, AG; Darbyshire, JH; Goodall, RL; Hooker, MH; Williams, IG | 1 |
| Calmy, A; Carey, DL; Carr, A; Cooper, DA; Emery, S; Law, MG; Samaras, K; Wand, H | 1 |
| Cammack, N; Dalgleish, AG; Sharland, M; Watkins, AM; Westby, M | 1 |
| Carter, LM; Ellis, BA; Peters, BS; Wolstencroft, RA | 1 |
| Albrecht, MA; Bosch, RJ; Dehlinger, M; Eron, J; Hammer, SM; Katzenstein, DA; Kessler, H; Liou, SH; Para, MF; Valdez, H | 1 |
| Barbour, JD; Deeks, SG; Grant, RM; Martin, JN | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
5 trial(s) available for nelfinavir and Disease Exacerbation
| Article | Year |
|---|---|
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
A virological benefit from an induction/maintenance strategy: the Forte trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Patient Compliance; Remission Induction; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Time Factors; Treatment Failure; United Kingdom; Viral Load | 2007 |
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Constitution; Cardiovascular Diseases; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Progression; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 2007 |
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Mutation; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Treatment Failure; Viral Load | 2001 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
8 other study(ies) available for nelfinavir and Disease Exacerbation
| Article | Year |
|---|---|
Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Disease Progression; Drug Screening Assays, Antitumor; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Intestinal Neoplasms; Lopinavir; Mesenchymal Stem Cells; Mice; Mice, SCID; Nelfinavir; Neoplasm Transplantation; Neoplastic Stem Cells; Pyrans; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Elongation Factor 2 Kinase; Female; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Nelfinavir; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; TOR Serine-Threonine Kinases; Tumor Burden | 2016 |
Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral; Time Factors; Treatment Refusal; Viral Load; Viremia | 2002 |
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure | 2006 |
Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Prognosis; Prospective Studies; Sex Characteristics; Treatment Outcome; Viral Load | 2007 |
Immune reconstitution in HAART-treated children with AIDS. Highly Active Anti-Retroviral Therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Child; Disease Progression; Female; Follow-Up Studies; Humans; Immunity, Cellular; Immunologic Memory; Lamivudine; Lymphocyte Count; Nelfinavir; Stavudine; Viral Load | 1998 |
Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Lymphocytes; Macrophage Inflammatory Proteins; Male; Nelfinavir; Stavudine; Viral Load; Viremia | 2000 |
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Viremia | 2002 |